5 results
DRS/A
ATXS
Astria Therapeutics Inc
5 Mar 15
Draft registration statement (amended)
12:00am
. The majority of subjects at a total daily dose of 1000 mg had gastrointestinal AEs. Overall, most AEs were mild in intensity but moderate intensity
DRS
ATXS
Astria Therapeutics Inc
23 Jan 15
Draft registration statement
12:00am
had gastrointestinal AEs. Overall, most AEs were mild in intensity but moderate intensity gastrointestinal AEs were reported, particularly at daily
- Prev
- 1
- Next